BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Cantor Fitzgerald
Dow
Novartis
Deloitte
Covington
Federal Trade Commission
Julphar
Accenture
Mallinckrodt

Generated: January 16, 2018

DrugPatentWatch Database Preview

Nps Pharms Inc Company Profile

« Back to Dashboard

Summary for Nps Pharms Inc
International Patents:75
US Patents:11
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Nps Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Nps Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,781,401 Glucagon-like peptide-2 analogs ➤ Subscribe
5,834,428 Glucagon-like peptide-2 and its therapeutic use ➤ Subscribe
8,933,039 Glucagon-like peptide-2 analogs ➤ Subscribe
5,990,077 Glucagon-like peptide-2 and its therapeutic use ➤ Subscribe
7,888,317 Glucagon-like peptide-2 and its therapeutic use ➤ Subscribe
7,049,284 Glucagon-like peptide-2 and its therapeutic use ➤ Subscribe
6,184,201 Intestinotrophic glucagon-like peptide-2 analogs ➤ Subscribe
8,846,625 Glucagon-like peptide-2 analogs ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Nps Pharms Inc Drugs

Supplementary Protection Certificates for Nps Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3 Finland ➤ Subscribe
153 Luxembourg ➤ Subscribe PRODUCT NAME: TEDUGLUTIDE SOUS TOUTES SES FORMES, TELLES QU ELLES SONT PROTEGEES PAR LE BREVET DE BASE
90009-7 Sweden ➤ Subscribe PRODUCT NAME: TEDUGLUTID; REG. NO/DATE: EU/1/12/787/001 20120830
2013 00012 Denmark ➤ Subscribe
13/006 Ireland ➤ Subscribe PRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
C0013 France ➤ Subscribe PRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
00578 Netherlands ➤ Subscribe PRODUCT NAME: TEDUGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE FORM THEREOF; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Cerilliant
Queensland Health
Cipla
Covington
Johnson and Johnson
Baxter
Dow
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot